Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks
Amgen’s Pavblu ‘Clearly Leaning Into Physician Economics’ According To Regeneron
Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.
